Psychiatric drug development has had major wins over the past year-and-a-half — think Karuna Pharmaceuticals' $14 billion takeout by Bristol Myers Squibb and the subsequent launch of a new schizophrenia therapy — but targeted neuropsychiatric drug development is still in its infancy. On a special edition of the BioCentury This Week podcast, BioCentury’s editors detail the promise of precision medicine in the space and break down what recent setbacks for key players mean for next steps in the clinic. The team is joined by special guest Peter Schueler, SVP of drug development solutions, neurosciences, at ICON, who delivers takeaways from this month’s the ECNP Roadmap Meeting on Precision Psychiatry in Frankfurt and a recent white paper by ICON. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/654903 00:01 - Sponsor Message: ICON Biotech02:20 - Precision Neuropsychiatry06:39 - Insights from ICON's Peter Schueler15:59 - Challenges in NeuropsychTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text

Ver todos los episodios